YD Bio (YDES) Total Non-Current Liabilities (2024 - 2025)
YD Bio's (YDES) quarterly Total Non-Current Liabilities came in at -$14991.5 billion in Q4 2025, down 397264.27% year-on-year from N/an in Q4 2024, and down 397264.27% on a QoQ basis from -$3.8 billion in Q4 2024.
YD Bio (YDES) Total Non-Current Liabilities (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Total Non-Current Liabilities data on file, last reported at -$14991.5 billion in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 397264.27% year-over-year to -$14991.5 billion in Q4 2025; TTM through Dec 2025 was -$14991.5 billion, a 397264.27% decrease from a year earlier, with the FY2025 full-year figure at -$14991.5 billion, down 397264.27% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at -$14991.5 billion, down from -$3.8 billion in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for YDES reached as high as -$3.8 billion in Q4 2024 and fell as low as -$14991.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | -14,991.47 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14,991.47 Bn |
| Dec 31, 2024 | -3.77 Bn |